P4‐301: Efficacy and Safety of MMFS‐01, a Synapse Density Enhancer, for Restoring Cognitive Ability in Age‐related Mild Cognitive Impairment: A Randomized, Double‐blind, Placebo‐controlled Trial

Guosong Liu,Jason Gregory Weinger,Zhong-Lin Lu,Feng Xue,Safa Sadeghpour

DOI: https://doi.org/10.1016/j.jalz.2015.08.131

2015-01-01

Abstract:Mild cognitive impairment (MCI), an age-related predementia cognitive disorder, affects the quality of life in the elderly. Currently, there is no effective treatment for preventing or reversing MCI. We developed MMFS-01, a synapse density enhancer, as synapse loss is one of the hallmarks of the aging brain and is strongly associated with the degree of cognitive impairment. In pre-clinical studies we demonstrated MMFS-01 is effective at reversing cognitive deficits in aging and AD model rodents. We conducted a randomized, double-blind, placebo-controlled, parallel-designed human clinical trial in elderly subjects (age 50-70) with age-related MCI. Subjects were treated with MMFS-01 (n=23) or placebo (n=21) for 12 weeks and their cognitive ability, emotion, sleep quality, and physiological changes were evaluated at baseline, Week 6, and Week 12. Overall cognitive ability was determined by a composite score of tests in four major cognitive domains including executive function (Trail Making Test part B), working memory (DigitSpan Test), attention (Flanker Test), and episodic memory (Face-Name Test). Emotion was evaluated by PANAS and HAM-A, and sleep quality was evaluated by PSQI. MMFS-01 was safe and well tolerated, with no severe adverse events and no difference in number of adverse events compared to placebo. With MMFS-01 treatment, overall cognition (Fluid Cognitive Ability) improved significantly at Week 6 (p=0.017) and maintained improvement at Week 12 (p=0.002) relative to placebo. The effect size was large; Cohen's d was 0.67 at Week 6 and 0.92 at Week 12. To further quantify the clinical significance of MMFS-01, results on TMT-B test were compared to normative data from age-matched cognitively-normal controls. MMFS-01 treatment restored impaired executive function of the subjects nearly back to that of age-matched cognitively-normal controls, suggesting MMFS-01 is clinically significant. The current study demonstrates the potential of MMFS-01 for treating cognitive impairment in elderly.